Last-Resort drug access for rare lung cancer patients
NCT ID NCT06841874
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is to give access when no other options are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- taletrectinib (a targeted cancer drug taken as a capsule)
- What this could lead to
- If it works, this could offer a treatment option for people with a specific type of lung cancer who have run out of standard choices.
- What could go wrong
- This is an expanded access program, not a formal trial, so data on effectiveness and safety are limited. The drug may not work for everyone and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOGENIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cutting radiation in CT scans: a new test of Ultra-Low-Dose imaging
- Can a simple CT scan catch lung cancer earlier in kuwait?
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?